Lymphatic invasion predicts sentinel lymph node metastasis and adverse outcome in primary cutaneous melanoma

J Cutan Pathol. 2017 Sep;44(9):734-739. doi: 10.1111/cup.12969. Epub 2017 Jun 19.

Abstract

Background: Sentinel lymph node (SLN) metastasis is a powerful predictor of survival in primary cutaneous melanoma. Lymphatic invasion (LI) may correlate with increased risk of SLN metastasis. Intralymphatic metastases, often difficult to detect on hematoxylin and eosin (H&E) stained sections, are readily identified with dual immunohistochemistry for melanocytic and lymphatic markers.

Methods: We used dual S100/D240 immunohistochemistry to detect LI in 125 melanomas from patients who underwent SLN biopsy and correlated LI with melanoma staging parameters and disease status.

Results: Dual immunohistochemistry allowed for the identification of LI in 33 cases (26%), compared to only 2% on H&E stained sections. Melanomas with LI showed greater thickness, higher mitotic rate and more frequent ulceration. Eleven of 33 cases with LI (33%) and 10 of 92 cases without LI (11%) were associated with a positive SLN (P = .006). More patients without LI were disease-free at last follow-up (80%) than patients with LI (50%; P = .002); LI was significantly associated with decreased progression-free survival.

Conclusion: The detection of LI is improved by dual immunohistochemistry and predicts SLN metastasis. The presence of LI may impact therapeutic planning in melanoma, such as the decision to perform a SLN biopsy.

Keywords: lymphatic invasion; melanoma; metastasis; sentinel lymph node.

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / analysis*
  • Disease-Free Survival
  • Female
  • Humans
  • Immunohistochemistry / methods*
  • Kaplan-Meier Estimate
  • Lymphatic Metastasis / diagnosis*
  • Lymphatic Metastasis / pathology
  • Male
  • Melanoma / pathology*
  • Melanoma, Cutaneous Malignant
  • Middle Aged
  • Proportional Hazards Models
  • Sentinel Lymph Node / pathology*
  • Skin Neoplasms / pathology*

Substances

  • Biomarkers, Tumor